Investors & Media

Apr 9, 2020 /

Apr 9, 2020 / Apr 9, 2020 /

Recent News

4/6/20

BELLUS Health Announces Completion of Dosing in Phase 2 RELIEF Trial with BLU-5937 for the Treatment of Refractory Chronic Cough
- Topline data on track for mid-year 2020 - LAVAL, Quebec --(BUSINESS WIRE)--Apr. 6, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or “BELLUS Health”) , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other...
Read More
3/25/20

BELLUS Health Announces Closing of Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations
- BELLUS now owns 100% of BLU-5937 and related P2X3 antagonist intellectual property with no future payments due - - 4.77 million BELLUS Health common shares issued in consideration - LAVAL, Quebec --(BUSINESS WIRE)--Mar. 25, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or...
Read More
3/23/20

BELLUS Health Announces Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations
- BELLUS to own 100% of BLU-5937 and related P2X3 antagonists intellectual property with no future payments due - - 4.77 million BELLUS Health common shares to be issued in consideration - LAVAL, Quebec --(BUSINESS WIRE)--Mar. 23, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (the “Company” or...
Read More